Navigation Links
Clinical studies show REMICADE reduces incidence of bowel surgeries in ulcerative colitis patients
Date:10/15/2007

PHILADELPHIA, PA, October 15, 2007- Clinical data presented today at the annual meeting of the American College of Gastroenterology (ACG) show that REMICADE significantly reduces the incidence of colectomy surgeries for patients with moderately to severely active ulcerative colitis (UC). According to a primary analysis of long-term extension data from the Active Ulcerative Colitis 1 and 2 trials (ACT trials), there is a 41 percent reduction in the incidence of colectomy, the surgical removal of the colon, in patients receiving REMICADE through 54 weeks, compared to those receiving placebo (p=0.015). REMICADE is the first and only biologic approved for the treatment of ulcerative colitis.

The analysis of the ACT extension trials included 728 patients from the initial ACT 1 and 2 trials, of whom 630 (86 percent) had complete follow-up through 54 weeks to ascertain whether they underwent colectomy surgery.

"These data illustrate that treatment with REMICADE significantly reduces the need for life-altering colectomy in patients with refractory ulcerative colitis," said Paul Rutgeerts, M.D., Ph.D., University Hospital Gasthuisberg, University of Leuven; Leuven, Belgium. "REMICADE may offer patients who fail other therapies the possibility of avoiding costly surgeries and hospitalizations while managing the symptoms of this debilitating disease long-term."

Separate data also presented at ACG today show the significant impact of colectomy on ulcerative colitis patients' use of healthcare services, including inpatient and outpatient hospital procedures, emergency room and physician visits, and laboratory and drug costs. A retrospective analysis of 411 patients, identified from the U.S. PharMetrics database as having UC and a colectomy between January 1, 2000, and June 30, 2005, found that total utilization of healthcare services increased significantly in the 12 months following colectomy, including inpatient and outpatient procedures (P
'/>"/>

Contact: Melissa Katz
215-325-6875
Centocor, Inc.
Source:Eurekalert

Page: 1 2 3 4 5 6

Related biology news :

1. Roche clinical trial registry and results database launched
2. NIAID begins clinical trial of West Nile virus vaccine
3. Compound might defeat African sleeping sickness, clinical trial beginning this month
4. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
5. Dalai Lama, top scientists to discuss science & clinical applications of meditation
6. Stem cells electric abilities might help their safe clinical use
7. Clinical trial to test stem cell approach for children with brain injury
8. New malaria vaccine shows promise in early clinical trial
9. Preclinical study of a new brain tumor therapy
10. Tramiprosate (Alzhemed? preclinical results published in Neurobiology of Aging
11. Fatty spheres loaded with siRNA shrink ovarian cancer tumors in preclinical trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... The shale gas boom has transformed the energy ... locations, it could cause conflict among the energy ... resources, say researchers. They add that degraded water ... adequate safeguards. The feature article appears in the ... , Meagan S. Mauter and colleagues point out ...
(Date:4/23/2014)... fiction, or simply cli-fi, is a newly coined term for ... warming. New research from University of Copenhagen shows how these ... simulate the potential consequences of climate change and imagine other ... scientific data on changes in the atmosphere; it is also ... the books we read and the films we see. And ...
(Date:4/23/2014)... disease is the first cause of dementia and affects ... cure has yet been found. One of the reasons ... cellular mechanisms which cause alterations in nerve transmissions and ... the disease., Researchers from the Institute of Neuroscience at ... mechanism involved in memory consolidation and were able to ...
Breaking Biology News(10 mins):How to avoid water wars between 'fracking' industry and residents 2Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3Loss of memory in Alzheimer's mice models reversed through gene therapy 2
... conducted at Western University (London, Canada) points to a ... (PTSD): utilising neurofeedback training to alter the plasticity of ... During neurofeedback, intentional control of one,s own ... brain-computer interface, which is able to represent graphically a ...
... those living with gastrointestinal disorders, such as ulcers or Crohn,s ... dietary changes. But what if one day treatment meant doing ... of inflamed or diseased tissues? That is where ... of Technology (MIT) are hoping their new study findings will ...
... Current pledges for greenhouse gas emission reductions are ... reach internationally agreed climate targets, according to new ... research teams coordinated by the International Institute for ... for Climate Impacts Research (PIK)., In the absence ...
Cached Biology News:Neurofeedback tunes key brain networks, improving subjective well-being in PTSD 2Manufacturing a new gut to treat GI diseases 2Continuing with pledge pathways to 2030 could push climate goals out of reach 2
(Date:1/15/2014)... 15, 2014 Freeslate, Inc ., ... announced that Lupin Limited, one of India’s top five ... Protégé PharmD System for high throughput solid form ... focused on a wide range of quality, affordable generic ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled a ... EST (11am PST), “Natural Language Processing: Converting Raw Data ... can turn raw, heterogeneous data into actionable knowledge to ... webinar will last approximately one hour. , Synopsis: Big ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging ... to serve the wound care market. , Free report ... was restructured with a seasoned management team and Board, ...
(Date:1/14/2014)... In recent years, growing suspicion about the pharmaceutical ... and promotion has led to unprecedented levels of public ... about the insidious impact of commercialization of research, has ... the world’s biggest pharmas for illegal marketing activities, allegations ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... 6, 2011 Biodel Inc. (Nasdaq: BIOD ... and CEO of Biodel, will present a corporate update ... January 13, 2011 at 9:30 a.m. Pacific Time (12:30 ... the development of new follow-on formulations of its lead ...
... OAKS, Calif. and MONROVIA, Calif., Jan. 6, 2011 ... announced today that they will collaborate to develop XmAb ... CD19 and CD32b.  XmAb5871 is currently in late-stage preclinical ... Under the terms of the agreement, Amgen has ...
... DIEGO, Jan. 6, 2011 Ardea Biosciences, Inc. (Nasdaq: ... results from its Phase 2b study of RDEA594 in ... treatment of gout, allopurinol.  Allopurinol currently accounts for greater ... prescription medications; however, in controlled trials, only 30-40% of ...
Cached Biology Technology:Amgen and Xencor Enter Option Deal to Co-Develop Xencor's Novel Antibody for Autoimmune Diseases 2Amgen and Xencor Enter Option Deal to Co-Develop Xencor's Novel Antibody for Autoimmune Diseases 3Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 2Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 3Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 4Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 5Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 6Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 7
... Synthesis Service provides you with ... knockdown any gene. We offer ... pairs with terminal dT nucleotides), ... lengths of your choice. Each ...
...
...
... Luminex 100 IS System is ideal for ... Beadlyte reagents. This system contains the new, ... by Luminex. The user can design specific ... The system has fully integrated graphing and ...
Biology Products: